A Study Assessing Rocatinlimab on Vaccine Antibody Response in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET - VOYAGER) (ROCKET-VOYAGER)

NCT05899816 PHASE3 COMPLETED

The primary objectives of this study are to: * estimate vaccine response in rocatinlimab group vs placebo group, assessed using antibody anti-tetanus response at Week 24 * estimate vaccine response in rocatinlimab group vs placebo group, assessed using antibody anti-meningococcal response at Week 24

Details

Lead sponsor	Amgen
Phase	PHASE3
Status	COMPLETED
Enrolment	221
Start date	Wed Jun 07 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Thu Nov 14 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Atopic Dermatitis
• Moderate-to-severe Atopic Dermatitis

Interventions

• Rocatinlimab
• Placebo

Countries

Canada, United States